Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Clinical trials

Inaxaplin for the treatment of APOL1-associated kidney disease

Nature Reviews Nephrology volume 19, pages 479–480 (2023)Cite this article

Subjects

APOL1 risk variants are associated with an increased risk of chronic kidney disease. Findings from a new study demonstrate that a small molecule, inaxaplin, inhibits APOL1 channel function; furthermore, inaxaplin reduced proteinuria in patients with focal segmental glomerulosclerosis and two APOL1 risk variants.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. United States Renal Data System. 2022 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States (NIH/NIDDK, 2022).

  2. Genovese, G. et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329, 841–845 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Daneshpajouhnejad, P., Kopp, J. B., Winkler, C. A. & Rosenberg, A. Z. The evolving story of apolipoprotein L1 nephropathy: the end of the beginning. Nat. Rev. Nephrol. 18, 307–320 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Parsa, A. et al. APOL1 risk variants, race, and progression of chronic kidney disease. N. Engl. J. Med. 369, 2183–2196 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Chen, D. P. et al. Kidney disease progression in membranous nephropathy among Black participants with high-risk APOL1 genotype. Clin. J. Am. Soc. Nephrol. 18, 337–343 (2023).

    PubMed  Google Scholar 

  6. Reeves-Daniel, A. M. et al. The APOL1 gene and allograft survival after kidney transplantation. Am. J. Transplant. 11, 1025–1030 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Olabisi, O. A. et al. APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases. Proc. Natl Acad. Sci. USA 113, 830–837 (2016).

    Article  CAS  PubMed  Google Scholar 

  8. Egbuna, O. et al. Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants. N. Engl. J. Med. 388, 969–979 (2023).

    Article  CAS  PubMed  Google Scholar 

  9. Troost, J. P. et al. An outcomes-based definition of proteinuria remission in focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 13, 414–421 (2018).

    Article  PubMed  Google Scholar 

  10. Kopp, J. B. et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J. Am. Soc. Nephrol. 22, 2129–2137 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

R.G. is supported by NIH/NICHD 1R21HD104176-01 and NIH/NIDDK 1R01DK134347-01.

Author information

Authors and Affiliations

  1. Department of Pediatrics, Division of Nephrology, Duke University Medical Center, Durham, NC, USA

    Rasheed Gbadegesin & Brandon Lane

  2. Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, USA

    Rasheed Gbadegesin & Brandon Lane

Authors
  1. Rasheed Gbadegesin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brandon Lane
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rasheed Gbadegesin.

Ethics declarations

Competing interests

R.G. is currently on the Advisory Board of Vertex Pharmaceuticals. He became a member of the Advisory Board following completion of the study and analysis of the results presented in the paper under discussion.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gbadegesin, R., Lane, B. Inaxaplin for the treatment of APOL1-associated kidney disease. Nat Rev Nephrol 19, 479–480 (2023). https://doi.org/10.1038/s41581-023-00721-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41581-023-00721-0

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing